Clinical Trial: A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants with Moderate-to-Severe Atopic Dermatitis

U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06815380) titled 'A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants with Moderate-to-Severe Atopic Dermatitis' on Feb. 04.

Brief Summary: The main purpose of this study is to evaluate the impact of lebrikizumab treatment on the overall well-being of adult participants with moderate-to-severe AD in real-world clinical practice settings across Europe, as measured using validated 5-item World Health Organization Well-being Index (WHO-5) and to investigate effectiveness and safety of lebrikizumab, treatment satisfaction, and long-term effect of lebrikizumab treatment on participant...